Last reviewed · How we verify
Aggressive Blood Pressure control
At a glance
| Generic name | Aggressive Blood Pressure control |
|---|---|
| Also known as | Accupril, Atenolol, Norvasc, Terazosin, Hydrochlorothiazide |
| Sponsor | Nova Scotia Health Authority |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Reversal of Atrial Substrate to Prevent Atrial (NA)
- Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation.
- Telehealth-Enhanced Assessment and Management (NA)
- Registry Study on "Control Nocturnal Hypertension to Reach the Target "
- Efficacy of Photobiomodulation on Wound Healing and Il-6 in Neuropathic Foot Ulcer (NA)
- POSITIVE Stroke Clinical Trial (NA)
- Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF (PHASE4)
- Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aggressive Blood Pressure control CI brief — competitive landscape report
- Aggressive Blood Pressure control updates RSS · CI watch RSS
- Nova Scotia Health Authority portfolio CI